ConductScience.org, home

Trial · NCT00590317

Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department

NCT00590317, Phase 2, Completed, Emory University; results first posted 2014-05-19

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department. Trials, record NCT00590317. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00590317

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department
NCT number
NCT00590317
Status
Completed
Phases
Phase 2
Enrollment
64 participants, actual
Lead sponsor
Emory University
Conditions
Nausea and Vomiting
Interventions
Prochlorperazine, Ondansetron
First posted
2008-01-10
Last updated
2014-05-19
Results first posted
2014-05-19
Limitations and caveats
Small sample size due to limited enrollment. Fewer patient in the Odansetron group were discharged home suggesting a possibly sicker baseline group. Complete data sets were not available for all patients due to sedation and participation.

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryVomiting at 0 to 120 Min.0 to 120 minutes after receiving medication
SecondaryNausea at 0 to 120 Min0 to 120 minutes after receiving medication100mm Visual Analog scale (VAS) Scale is from 0 mm to 100 mm 0mm = no nausea 100mm = severe nausea
SecondaryAkithisia at 0 to 120 Min0 to 120 min after receiving medication

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYVomiting at 0 to 120 Min.0 to 120 minutes after receiving medicationConvenience samplenumber of participants exp vomitingNUMBER
SECONDARYNausea at 0 to 120 Min0 to 120 minutes after receiving medicationunits on a scaleGEOMETRIC_MEAN
SECONDARYAkithisia at 0 to 120 Min0 to 120 min after receiving medicationno. participants exp akathisiaNUMBER

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Vomiting at 0 to 120 Min.Prochlorperazine1number of participants exp vomiting
Vomiting at 0 to 120 Min.Ondansetron4number of participants exp vomiting
Nausea at 0 to 120 MinProchlorperazine16.8Standard Deviation 21.9units on a scale
Nausea at 0 to 120 MinOndansetron34.3Standard Deviation 31.7units on a scale
Akithisia at 0 to 120 MinProchlorperazine3no. participants exp akathisia
Akithisia at 0 to 120 MinOndansetron1no. participants exp akathisia

Participant flow6

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDProchlorperazine32
Overall StudySTARTEDOndansetron32
Overall StudyCOMPLETEDProchlorperazine31
Overall StudyCOMPLETEDOndansetron27
Overall StudyNOT COMPLETEDProchlorperazine1
Overall StudyNOT COMPLETEDOndansetron5

Adverse events2

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEvents
seriousAkathisiaNervous system disordersProchlorperazine3323
seriousAkathisiaNervous system disordersOndansetron1321

Adverse event totals6

The totals the trial posted for each group.

TotalGroupAffectedAt risk
Total, all-cause mortalityProchlorperazine
Total, all-cause mortalityOndansetron
Total, other adverse eventsProchlorperazine032
Total, other adverse eventsOndansetron032
Total, serious adverse eventsProchlorperazine332
Total, serious adverse eventsOndansetron132

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Prochlorperazine vs Ondansetron: serious adverse events

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00590317

GET https://conductscience.org/api/trials/v1/NCT00590317/registered